Deals in Depth: March 2011
Takeda's deals with Intra-Cellular Therapies ($500 million) and Dainippon Sumitomo Pharma ($302 million) for their neurology assets topped the alliance list. Blood processing firm CaridianBCT was scooped up by Terumo for $2.6 billion in the biggest M&A of the month. Biopharma companies raised significantly less capital in March - $676 million - pulling in less than half of February's $1.9 billion. Total device fundraising drppoed from $367 million to $184 million.
You may also be interested in...
New report shows average out-of-pocket cost per prescription of $10.67 in 2019 was unchanged from 2018. But while the number of dispensed drugs barely increased, sales jumped more than 5%.
The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.